Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
Abstract Background Temozolomide (TMZ) is the preferred chemotherapy strategy for glioma therapy. As a second-generation alkylating agent, TMZ provides superior oral bio-availability. However, limited response rate (less than 50%) and high incidence of drug resistance seriously restricts TMZ’s appli...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-023-04042-5 |
| _version_ | 1827982884957323264 |
|---|---|
| author | Xiaoying Hou Hongzhi Du Yufei Deng Haiping Wang Jinmi Liu Jialu Qiao Wei Liu Xiji Shu Binlian Sun Yuchen Liu |
| author_facet | Xiaoying Hou Hongzhi Du Yufei Deng Haiping Wang Jinmi Liu Jialu Qiao Wei Liu Xiji Shu Binlian Sun Yuchen Liu |
| author_sort | Xiaoying Hou |
| collection | DOAJ |
| description | Abstract Background Temozolomide (TMZ) is the preferred chemotherapy strategy for glioma therapy. As a second-generation alkylating agent, TMZ provides superior oral bio-availability. However, limited response rate (less than 50%) and high incidence of drug resistance seriously restricts TMZ’s application, there still lack of strategies to increase the chemotherapy sensitivity. Methods Luci-GL261 glioma orthotopic xenograft model combined bioluminescence imaging was utilized to evaluate the anti-tumor effect of TMZ and differentiate TMZ sensitive (S)/non-sensitive (NS) individuals. Integrated microbiomics and metabolomics analysis was applied to disentangle the involvement of gut bacteria in TMZ sensitivity. Spearman’s correlation analysis was applied to test the association between fecal bacteria levels and pharmacodynamics indices. Antibiotics treatment combined TMZ treatment was used to confirm the involvement of gut microbiota in TMZ response. Flow cytometry analysis, ELISA and histopathology were used to explore the potential role of immunoregulation in gut microbiota mediated TMZ response. Results Firstly, gut bacteria composition was significantly altered during glioma development and TMZ treatment. Meanwhile, in vivo anti-cancer evaluation suggested a remarkable difference in chemotherapy efficacy after TMZ administration. Moreover, 16s rRNA gene sequencing and non-targeted metabolomics analysis revealed distinct different gut microbiota and immune infiltrating state between TMZ sensitive and non-sensitive mice, while abundance of differential gut bacteria and related metabolites was significantly correlated with TMZ pharmacodynamics indices. Further verification suggested that gut microbiota deletion by antibiotics treatment could accelerate glioma development, attenuate TMZ efficacy and inhibit immune cells (macrophage and CD8α+ T cell) recruitment. Conclusions The current study confirmed the involvement of gut microbiota in glioma development and individualized TMZ efficacy via immunomodulation, hence gut bacteria may serve as a predictive biomarker as well as a therapeutic target for clinical TMZ application. |
| first_indexed | 2024-04-09T22:40:10Z |
| format | Article |
| id | doaj.art-1b5663a4788244b697639334664472d4 |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-04-09T22:40:10Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-1b5663a4788244b697639334664472d42023-03-22T12:14:33ZengBMCJournal of Translational Medicine1479-58762023-03-0121111510.1186/s12967-023-04042-5Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in gliomaXiaoying Hou0Hongzhi Du1Yufei Deng2Haiping Wang3Jinmi Liu4Jialu Qiao5Wei Liu6Xiji Shu7Binlian Sun8Yuchen Liu9Wuhan Institute of Biomedical Sciences, School of Medicine, Jianghan UniversitySchool of Pharmacy, Hubei University of Chinese MedicineWuhan Institute of Biomedical Sciences, School of Medicine, Jianghan UniversityWuhan Institute of Biomedical Sciences, School of Medicine, Jianghan UniversityWuhan Institute of Biomedical Sciences, School of Medicine, Jianghan UniversityWuhan Institute of Biomedical Sciences, School of Medicine, Jianghan UniversityWuhan Institute of Biomedical Sciences, School of Medicine, Jianghan UniversityWuhan Institute of Biomedical Sciences, School of Medicine, Jianghan UniversityWuhan Institute of Biomedical Sciences, School of Medicine, Jianghan UniversityWuhan Institute of Biomedical Sciences, School of Medicine, Jianghan UniversityAbstract Background Temozolomide (TMZ) is the preferred chemotherapy strategy for glioma therapy. As a second-generation alkylating agent, TMZ provides superior oral bio-availability. However, limited response rate (less than 50%) and high incidence of drug resistance seriously restricts TMZ’s application, there still lack of strategies to increase the chemotherapy sensitivity. Methods Luci-GL261 glioma orthotopic xenograft model combined bioluminescence imaging was utilized to evaluate the anti-tumor effect of TMZ and differentiate TMZ sensitive (S)/non-sensitive (NS) individuals. Integrated microbiomics and metabolomics analysis was applied to disentangle the involvement of gut bacteria in TMZ sensitivity. Spearman’s correlation analysis was applied to test the association between fecal bacteria levels and pharmacodynamics indices. Antibiotics treatment combined TMZ treatment was used to confirm the involvement of gut microbiota in TMZ response. Flow cytometry analysis, ELISA and histopathology were used to explore the potential role of immunoregulation in gut microbiota mediated TMZ response. Results Firstly, gut bacteria composition was significantly altered during glioma development and TMZ treatment. Meanwhile, in vivo anti-cancer evaluation suggested a remarkable difference in chemotherapy efficacy after TMZ administration. Moreover, 16s rRNA gene sequencing and non-targeted metabolomics analysis revealed distinct different gut microbiota and immune infiltrating state between TMZ sensitive and non-sensitive mice, while abundance of differential gut bacteria and related metabolites was significantly correlated with TMZ pharmacodynamics indices. Further verification suggested that gut microbiota deletion by antibiotics treatment could accelerate glioma development, attenuate TMZ efficacy and inhibit immune cells (macrophage and CD8α+ T cell) recruitment. Conclusions The current study confirmed the involvement of gut microbiota in glioma development and individualized TMZ efficacy via immunomodulation, hence gut bacteria may serve as a predictive biomarker as well as a therapeutic target for clinical TMZ application.https://doi.org/10.1186/s12967-023-04042-5TemozolomideFecal microbiomeFunctional MetabolomicsIndividualized efficacyGlioma |
| spellingShingle | Xiaoying Hou Hongzhi Du Yufei Deng Haiping Wang Jinmi Liu Jialu Qiao Wei Liu Xiji Shu Binlian Sun Yuchen Liu Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma Journal of Translational Medicine Temozolomide Fecal microbiome Functional Metabolomics Individualized efficacy Glioma |
| title | Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma |
| title_full | Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma |
| title_fullStr | Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma |
| title_full_unstemmed | Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma |
| title_short | Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma |
| title_sort | gut microbiota mediated the individualized efficacy of temozolomide via immunomodulation in glioma |
| topic | Temozolomide Fecal microbiome Functional Metabolomics Individualized efficacy Glioma |
| url | https://doi.org/10.1186/s12967-023-04042-5 |
| work_keys_str_mv | AT xiaoyinghou gutmicrobiotamediatedtheindividualizedefficacyoftemozolomideviaimmunomodulationinglioma AT hongzhidu gutmicrobiotamediatedtheindividualizedefficacyoftemozolomideviaimmunomodulationinglioma AT yufeideng gutmicrobiotamediatedtheindividualizedefficacyoftemozolomideviaimmunomodulationinglioma AT haipingwang gutmicrobiotamediatedtheindividualizedefficacyoftemozolomideviaimmunomodulationinglioma AT jinmiliu gutmicrobiotamediatedtheindividualizedefficacyoftemozolomideviaimmunomodulationinglioma AT jialuqiao gutmicrobiotamediatedtheindividualizedefficacyoftemozolomideviaimmunomodulationinglioma AT weiliu gutmicrobiotamediatedtheindividualizedefficacyoftemozolomideviaimmunomodulationinglioma AT xijishu gutmicrobiotamediatedtheindividualizedefficacyoftemozolomideviaimmunomodulationinglioma AT binliansun gutmicrobiotamediatedtheindividualizedefficacyoftemozolomideviaimmunomodulationinglioma AT yuchenliu gutmicrobiotamediatedtheindividualizedefficacyoftemozolomideviaimmunomodulationinglioma |